HDL-C and HDL-C/ApoA-I Predict Long-Term Progression of Glycemia in Established Type 2 Diabetes

被引:62
作者
Waldman, Boris [1 ]
Jenkins, Alicia J.
Davis, Timothy M. E. [2 ]
Taskinen, Marja-Riitta [3 ]
Scott, Russell [4 ]
O'Connell, Rachel L. [1 ]
Gebski, Val J. [1 ]
Ng, Martin K. C. [5 ]
Keech, Anthony C. [1 ,5 ]
机构
[1] Univ Sydney, Sydney Med Sch, NHMRC Clin Trials Ctr, Sydney, NSW 2006, Australia
[2] Univ Western Australia, Sch Med, Fremantle, WA, Australia
[3] Univ Helsinki, Res Programs, Unit Diabet & Obes, Cardiovasc Res Grp,HUCH Heart & Lung Ctr, Helsinki, Finland
[4] Christchurch Hosp, Lipid & Diabet Res Grp, Christchurch, New Zealand
[5] Royal Prince Alfred Hosp, Dept Cardiol, Sydney, NSW, Australia
基金
英国医学研究理事会; 澳大利亚国家健康与医学研究理事会;
关键词
INSULIN-RESISTANCE ATHEROSCLEROSIS; CARDIOVASCULAR RISK-FACTORS; NUCLEAR-MAGNETIC-RESONANCE; BETA-CELL FUNCTION; LIPOPROTEIN PARTICLE-SIZE; APOLIPOPROTEIN-A-I; GLUCOSE-METABOLISM; FENOFIBRATE INTERVENTION; LIFE-STYLE; CHOLESTEROL;
D O I
10.2337/dc13-2738
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE Low HDL cholesterol (HDL-C) and small HDL particle size may directly promote hyperglycemia. We evaluated associations of HDL-C, apolipoprotein A-I (apoA-I), and HDL-C/apoA-I with insulin secretion, insulin resistance, HbA(1c), and long-term glycemic deterioration, reflected by initiation of pharmacologic glucose control. RESEARCH DESIGN AND METHODS The 5-year Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study followed 9,795 type 2 diabetic subjects. We calculated baseline associations of fasting HDL-C, apoA-I, and HDL-C/apoA-I with HbA(1c) and, in those not taking exogenous insulin (n = 8,271), with estimated beta-cell function (homeostasis model assessment of b-cell function [HOMA-B]) and insulin resistance (HOMA-IR). Among the 2,608 subjects prescribed lifestyle only, Cox proportional hazards analysis evaluated associations of HDL-C, apoA-I, and HDL-C/apoA-I with subsequent initiation of oral hypoglycemic agents (OHAs) or insulin. RESULTS Adjusted for age and sex, baseline HDL-C, apoA-I, and HDL-C/apoA-I were inversely associated with HOMA-IR (r = -0.233, -0.134, and -0.230; all P < 0.001; n = 8,271) but not related to HbA(1c) (all P > 0.05; n = 9,795). ApoA-I was also inversely associated with HOMA-B (r = -0.063; P = 0.002; n = 8,271) adjusted for age, sex, and HOMA-IR. Prospectively, lower baseline HDL-C and HDL-C/apoA-I levels predicted greater uptake (per 1-SD lower: hazard ratio [HR] 1.13 [CI 1.07-1.19], P < 0.001; and HR 1.16 [CI 1.10-1.23], P < 0.001, respectively) and earlier uptake (median 12.9 and 24.0 months, respectively, for quartile 1 vs. quartile 4; both P < 0.01) of OHAs and insulin, with no difference in HbA(1c) thresholds for initiation (P = 0.87 and P = 0.81). Controlling for HOMA-IR and triglycerides lessened both associations, but HDL-C/apoA-I remained significant. CONCLUSIONS HDL-C, apoA-I, and HDL-C/apoA-I were associated with concurrent insulin resistance but not HbA(1c). However, lower HDL-C and HDL-C/apoA-I predicted greater and earlier need for pharmacologic glucose control.
引用
收藏
页码:2351 / 2358
页数:8
相关论文
共 40 条
[1]   Role of HDL Cholesterol and Estimates of HDL Particle Composition in Future Development of Type 2 Diabetes in the General Population: The PREVEND Study [J].
Abbasi, Ali ;
Corpeleijn, Eva ;
Gansevoort, Ron T. ;
Gans, Rijk O. B. ;
Hillege, Hans L. ;
Stolk, Ronald P. ;
Navis, Gerjan ;
Bakker, Stephan J. L. ;
Dullaart, Robin P. F. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (08) :E1352-E1359
[2]   The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481] [J].
Barter, P. ;
Best, J. ;
Colman, P. ;
d'Emden, M. ;
Davis, T. ;
Drury, P. ;
Ehnholm, C. ;
Glasziou, P. ;
Hunt, D. ;
Keech, A. ;
Kesaniemi, Y. A. ;
Laakso, M. ;
Scott, R. ;
Simes, R. J. ;
Sullivan, D. ;
Taskinen, M-R ;
Whiting, M. ;
Ansquer, J-C ;
Fraitag, B. ;
Anderson, N. ;
Hankey, G. ;
Hunt, D. ;
Lehto, S. ;
Mann, S. ;
Romo, M. ;
Li, L. P. ;
Hennekens, C. ;
MacMahon, S. ;
Pocock, S. ;
Tonkin, A. ;
Wilhelmsen, L. ;
Forder, P. ;
Akauola, H. ;
Alford, F. ;
Barter, P. ;
Beinart, I. ;
Best, J. ;
Bohra, S. ;
Boyages, S. ;
Colman, P. ;
Connor, H. ;
Darnell, D. ;
Davis, T. ;
Davoren, P. ;
Lepre, F. ;
De Looze, F. ;
d'Emden, M. ;
Duffield, A. ;
Fassett, R. ;
Flack, J. .
CARDIOVASCULAR DIABETOLOGY, 2004, 3 (1)
[3]   Glycemic Control Over 5 Years in 4,900 People With Type 2 Diabetes Real-world diabetes therapy in a clinical trial cohort [J].
Best, James D. ;
Drury, Paul L. ;
Davis, Timothy M. E. ;
Taskinen, Marja-Riitta ;
Kesaniemi, Y. Antero ;
Scott, Russell ;
Pardy, Christopher ;
Voysey, Merryn ;
Keech, Anthony C. .
DIABETES CARE, 2012, 35 (05) :1165-1170
[4]   β-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment [J].
Brunham, Liam R. ;
Kruit, Janine K. ;
Pape, Terry D. ;
Timmins, Jenelle M. ;
Reuwer, Anne Q. ;
Vasanji, Zainisha ;
Marsh, Brad J. ;
Rodrigues, Brian ;
Johnson, James D. ;
Parks, John S. ;
Verchere, C. Bruce ;
Hayden, Michael R. .
NATURE MEDICINE, 2007, 13 (03) :340-347
[5]  
Calculator HOMA, 2014, HOMA CALCULATOR FAQ
[6]   Cardiovascular disease risk factors predict the development of type 2 diabetes - The Insulin Resistance Atherosclerosis Study [J].
D'Agostino, RB ;
Hamman, RF ;
Karter, AJ ;
Mykkanen, L ;
Wagenknecht, LE ;
Haffner, SM .
DIABETES CARE, 2004, 27 (09) :2234-2240
[7]   The emerging role of HDL in glucose metabolism [J].
Drew, Brian G. ;
Rye, Kerry-Anne ;
Duffy, Stephen J. ;
Barter, Philip ;
Kingwell, Bronwyn A. .
NATURE REVIEWS ENDOCRINOLOGY, 2012, 8 (04) :237-245
[8]   High-Density Lipoprotein Modulates Glucose Metabolism in Patients With Type 2 Diabetes Mellitus [J].
Drew, Brian G. ;
Duffy, Stephen J. ;
Formosa, Melissa F. ;
Natoli, Alaina K. ;
Henstridge, Darren C. ;
Penfold, Sally A. ;
Thomas, Walter G. ;
Mukhamedova, Nigora ;
de Courten, Barbora ;
Forbes, Josephine M. ;
Yap, Felicia Y. ;
Kaye, David M. ;
van Hall, Gerrit ;
Febbraio, Mark A. ;
Kemp, Bruce E. ;
Sviridov, Dmitri ;
Steinberg, Gregory R. ;
Kingwell, Bronwyn A. .
CIRCULATION, 2009, 119 (15) :2103-U134
[9]   Pancreatic β-cell function relates positively to HDL functionality in well-controlled Type 2 diabetes mellitus [J].
Dullaart, Robin P. F. ;
Annema, Wijtske ;
de Boer, Jan Freark ;
Tietge, Uwe J. F. .
ATHEROSCLEROSIS, 2012, 222 (02) :567-573
[10]   The natural course of β-cell function in nondiabetic and diabetic individuals -: The insulin resistance atherosclerosis study [J].
Festa, A ;
Williams, K ;
D'Agostino, R ;
Wagenknecht, LE ;
Haffner, SM .
DIABETES, 2006, 55 (04) :1114-1120